Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on development and commercialization of therapies for patients living with autoimmune diseases. It is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, its lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Orelabrutinib is a highly selective central nervous system (CNS)-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib's mechanism of action targets pathogenic B cells not only in periphery but also within CNS. Its earlier stage programs include ZB021, an oral small molecule IL-17AA/AF inhibitor; ZB022, a preclinical, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcgRIIb monoclonal antibody.